The effect of cognitive function as measured by repeated cognitive measures after 12 weeks treatment with donepezil
Study identifier:D2285M00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-blind, Placebo-controlled, Parallel design, Multicentre Study in Patients with Mild to Moderate Alzheimer’s Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 weeks
Medical condition
Alzheimer's disease
Phase
N/A
Healthy volunteers
No
Study drug
Donepezil, Placebo to match Aricept
Sex
All
Actual Enrollment
155
Study type
Interventional
Age
55 Years - 85 Years
Date
Study Start Date: 01 Dec 2009
Primary Completion Date: 01 Jan 2011
Study Completion Date: 01 Jan 2011
Study design
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days) | Drug: Donepezil 5 mg capsule, orally, once daily, first 14 days of treatment Other Name: Aricept Drug: Donepezil 10 mg, orally, once daily, for remaining 70 days of treatment Other Name: Aricept |
| Placebo Comparator: 2 | Drug: Placebo to match Aricept Placebo capsule, orally, 84 days of treatment |
Contacts
Investigators
Principal Investigator
Malene Jensen
Study Delievery Director, AstraZeneca
